A Fair Criticism Deserves a Response

Subscriber jryan (below) delivered some reasonable comments and criticism yesterday in the Comments Section. 

Basically he said he is “getting sick of reading about cannabis and Fin TV commentary” — and he wants more (long) stock suggestions, etc.  

I wanted to respond in the first column of the day. 

* Few longs have represented value to me as I have been unduly negative for a lengthy period of time. I take ownership of that.

* The stocks that I have owned have recently been Staples ($KO, $PEP, $PG and $KMB), selected cannabis names and some others. The consumer nondurable stocks have been fine recently (and I have taken profits in them). We shall see about cannabis — a speculative sector and my focus has been intermediate-term based on the improved likelihood of rescheduling and other factors clearly delineated in my Diary.

*As to the CNBC constructive criticism. I point these out not only as an advocate of the retail viewer that should see timestamps (panelists taking ownership) and observe better company interviews, but so they can evaluate the merits and process of the panelists’ recommendations and become better-informed investors through more hard-hitting interviews (that serve more than as a marketing tool of companies). 

* But the criticism directed to Fin TV also is intended to highlight investment recommendations from panelists and guests that I strongly disagree with. Choosing stocks to avoid (in that FIN TV criticism) can be as valuable or even more valuable than choosing stocks to buy. Consider my negative comments towards $BA, $BABA, $META, $UBER, $NFLX, $RDDT, $TTAN, $DIS, $CLF, $MRNA and $UNH (a few years back) etc. that were mostly confidently and strenuously recommended on CNBC. 

* My “More Tales From Nvidia” series is intended to deliver the idea that the functionality, productivity and ROIC on the enormous capital spend may disappoint the many and multitude of optimists on AI. I have felt that my contrarian and non herd-like observations were valuable in a backdrop of near-universal bullishness (that is readily and frequently available from the buy/sell sides, panelists and guests). My view was that dwelling on “More Tales” had statistical value in that over 40% of the S&P is comprised of large-cap tech.   

* As to specific AI beneficiaries, I have admitted (often) of missing $MSFT and $GOOGL. The valuation on $AAPL seems foolish to me — the shares have prospered and I have been wrong.  But the others ($META, $AMZN and even $NVDA) have not set the world on fire this year. As to memory and chip stocks, they have been “the world’s fair” up until the summer but awful since late June. Not only do I think these companies are “overearning,” but the volatility is not for me and not consistent and doesn’t conform with my appetite for risk. 

*  The financial stocks were quite strong until early summer. I repeatedly cautioned not to embrace banks, brokers and private equity shares (I successfully shorted $BX, $KKR and $APOL since then). Viewed by panelists as perhaps the best “value play,” financials have been dismal over the last four months.  We avoided this decline (in $C, $JPM, $BAC, $GS, $MS et al).

* The stocks that I have been short in the AI sphere have been terrific (to the downside) — $ORCL and $CRWV. (Avoiding them as longs has also been a valuable contribution.) My recent foray into shorting NVDA was profitable also. 

* As to my preoccupation with CNBC I suggest taking the number of words written about FIN TV and divide it by the number of words written on other subjects daily. You will find my criticism is dwarfed by my other columns. In the scheme of things my criticism is de minimis. 

* Finally, to jryan I say there are many other contributors that actively recommend longs and provide a valuable service.

All this said I am imperfect.

I take ownership of my mistakes.

The transparency of my Diary exposes my blemishes. 

I believe jryan has some good points and I will purposefully look for more long ideas in the future. 

I truly appreciate jryan’s comments and I have tried to respond to his concerns:

jryan

Just a thought. There used to be a lot of different investment ideas, stock suggestions etc., but all it seems to be now is cannabis and CNBC commentary, which I don’t watch anyway. Kind of getting sick of it, especially the cannabis info, is it ever going to pay off? Likely, but it will be quite a while from today, if ever. But at least it’s easier to scroll through the commentary and use less time.

Position: Long KO (VS), PG (VS), KMB (VS), MSOS common (VL) and calls (VS), VRNO (VS), GLAS (S), GTBIF (S), TRLV (VS), CURLF (VS); Short AAPL (S)

My Comment of the Day


Dougie Kass

3m ago

The tide is going out and now you understand my resentment towards Fin TV.

Look at their favorite stocks – $BABA $UBER $NFLX $SHAK $GEV $CAT Paramount, $BA, $RDDT  the banks/brokers/private equity et al

They are swimming naked.

Memo to retail investors – they will not take ownership of their mistakes, the will continue to smile, they will be confident in view, they will take your assets. 

They will cost you money. 

Turn off your TVs.

Positions: None 

My Comment of the Day (Part Trois)


Dougie Kass

39m ago

I am no longer dwelling on the BS from panelists on the shows.

But as I have warned when the tide goes out you will realize the absence of analytical rigor and process.

The panelists, you will also realize, will not revisit their losers.

They will never timestamp because viewers would realize the “jig is up.”

Panelists want to seem/look smart – they want to polish their images as they are asset gatherers or are selling a service.

But look at the shares of  homebuilders, $RDDT, $SHAK, $BABA, $TTAN, $GEV, $UBER, $NFLX and the many others that were confidently recommended by the panelists of floor traders, veterans of Long Island Boiler Room brokerages, phony technical analysts (who don’t even know what a fractal is or who Mandlebrot was!).

I have highlighted their BS as an advocate of the retail viewer who all generally think being a regular panelist on CNBC means alot.

It means virtually nothing.   

Positions: None.

Upside, Downside Movers in the Morning

Source: TradeTheNews

Upside

– $VTGN +59.5% (extends the prior-session rally after preliminary PALISADE-4 open-label extension data for fasedienol in social anxiety disorder)

– $GRML +24.0% (no clear fresh catalyst identified; exceptionally heavy-volume small-cap move)

– $WOR +15.5% (Q1 beat as stronger Building Products results and data-center demand lifted performance)

– $TLSI +15.0% (FDA grants 510(k) clearance for the TriNav Advance drug-delivery device)

– $IONQ +13.0% (demonstrates an end-to-end real-time quantum error-correction decoder running on a standard CPU)

– $CBRL +9.0% (Q4 profit beat and FY27 EBITDA outlook pointed to a sharp recovery despite lower sales)

– $QUBT +4.0% (quantum-computing sympathy following IONQ’s error-correction milestone)

– $CART +3.0% (expands its AI-shopping partnership network)

– $APH +3.0% (Bernstein initiates coverage at Outperform)

Downside

– $JAGX -48.0% (reverses sharply after the prior session’s roughly twelvefold FDA-fee-waiver-driven surge)

– $INNV -8.5% (10M-share secondary offering by selling stockholders creates a near-term stock overhang)

– $VOYG -7.5% ($350M convertible-senior-notes offering raises dilution concerns)

– $ASTH -7.5% (no clear fresh catalyst identified; renewed selling follows the recent short report questioning accounting estimates)

– $BMEA -7.0% (launches an underwritten common-stock and pre-funded-warrant offering)

– $AU -4.5%, GFI -4.5%, AG -3.0%, NEM -2.0% (precious-metals miners fall as gold and silver prices retreat)

– $BABA -3.0% (China ADR weakness ahead of the U.S.-China summit as mainland equities decline)

– $APP -2.5% (extends the AI-disruption selloff on concern consumer agents could pressure ad-tech economics)